Biotech Stocks In Boom: Gilead Sciences Inc. (NASDAQ:GILD), Genetic Technologies Limited (NASDAQ:GENE), Exelixis (NASDAQ:EXEL), Achillion Pharmaceuticals (NASDAQ:ACHN), ZIOPHARM Oncology (NASDAQ:ZIOP)

On 3 February, Gilead Sciences, Inc. (NASDAQ:GILD) announced its results of operations for the fourth quarter and full year 2014. Total revenues for the fourth quarter of 2014 were $7.3 billion compared to $3.1 billion for the fourth quarter of 2013. On Wednesday shares of Gilead Sciences Inc. (NASDAQ:GILD) closed at $98.47. Company’s sales growth for last 5 years was 28.80% and EPS growth for next 5 years is recorded as 25.20%.

On 29 January, Genetic Technologies Limited (NASDAQ:GENE) reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus(R) to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. Genetic Technologies Limited (NASDAQ:GENE) in last trading activity increased 8.43% to close at $4.50. Company weekly performance is 27.48% while its quarterly performance stands at 143.24%. Genetic Technologies Limited (NASDAQ:GENE) is -62.66% away from its 52 week high.

Exelixis, Inc. (NASDAQ:EXEL) announced that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 24, 2015 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the results and provide a general business update. On last trading day Exelixis, Inc. (NASDAQ:EXEL) increased 2.51% to close at $2.24. Its volatility for the week is 10.29% while volatility for the month is 8.37%. EXEL’s sales growth for past 5 years was -23.30% and its EPS growth for past 5 years was 2.90%. Exelixis, Inc. (NASDAQ:EXEL) monthly performance is 36.06%.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $10.25 per share. All of the shares in the offering will be sold by Achillion. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has 44.11% insider ownership while its institutional ownership stands at 95.50%. In last trading activity company’s stock closed at $10.87.

On February 3, 2015, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), relating to an underwritten public offering of 10,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). On last trading day ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) increased 1.68% to close at $9.06. Its volatility for the week is 6.97% while volatility for the month is 10.68%. ZIOP’s EPS growth for past 5 years was 11.10%. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) monthly performance is 52.78%.

Leave a Reply

Your email address will not be published. Required fields are marked *